Avanir Pharmaceuticals, Inc. (AVNR) Reports In-Line Q4 EPS Loss of $0.14
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Financial Fact:
Loss from operations: -11.89M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Loss from operations: -11.89M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $4.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
- Bit Digital (BTBT) Misses Q2 EPS by 27c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
